Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Kezar Life Sciences Inc

2KZ
Current price
0.51 EUR 0 EUR (0.00%)
Last closed 0.57 USD
ISIN US49372L1008
Sector Healthcare
Industry Biotechnology
Exchange Stuttgart Exchange
Capitalization 40 822 348 USD
Yield for 12 month -53.28 %
1Y
3Y
5Y
10Y
15Y
2KZ
21.11.2021 - 28.11.2021

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 4000 Shoreline Court, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.33 USD

P/E ratio

Dividend Yield

Current Year

+7 000 000 USD

Last Year

Current Quarter

Last Quarter

Current Year

+5 934 000 USD

Last Year

-1 022 999 USD

Current Quarter

-261 000 USD

Last Quarter

-260 000 USD

Key Figures 2KZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -98 462 000 USD
Operating Margin TTM -1422.01 %
PE Ratio
Return On Assets TTM -28.07 %
PEG Ratio
Return On Equity TTM -51.48 %
Wall Street Target Price 7.33 USD
Revenue TTM 7 000 000 USD
Book Value 2.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.35 USD
Diluted Eps TTM -1.35 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 2KZ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 2KZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 2KZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 5.8318
Enterprise Value EBITDA 0.0597
Price Book MRQ 0.2697

Financials 2KZ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 2KZ

For 52 weeks

0.54 USD 1.32 USD
50 Day MA 0.61 USD
Shares Short Prior Month 1 039 641
200 Day MA 0.79 USD
Short Ratio 2.37
Shares Short 853 643
Short Percent 1.2 %